Search Results

At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional Stuart’s current research, in the Receptor Biology Lab, focuses on the development of novel GPCR-based therapeutics

particular, drives tumor growth via effects on GBM stem cell self-renewal and metabolism, but also has a therapeutically has been particularly interested in the role adhesion GPCRs play in glioblastoma biology and their therapeutic Javitch1,2 1Departments of Psychiatry and Molecular Pharmacology and Therapeutics, Columbia University , New York, NY 10032; 2Division of Molecular Therapeutics, New York State Psychiatric Institute, New

GPCR signal transduction and neuroscience, and she has expanded it in the areas of drug discovery and structural Her research focuses on the structure and function of GTP binding proteins and the molecular mechanisms studying G protein coupled signal transduction for many years and has made key discoveries in G protein structure

Axel Brunger’s lab at Stanford University to study the structure and function of cell-adhesion proteins journey of studying adhesion GPCRs, the challenges he faced, and the progress made in understanding their structure adhesion GPCRs, outlining his collaborations, challenges, and the progress made in understanding their structure collaborations and improved their understanding of the GPCRs through various approaches, including structural the field has seen significant growth, with important discoveries such as the transmembrane region structures

Yamina underscores the therapeutic potential of GPR65, especially in the context of cancer immunotherapy , and how understanding receptor activity in acidic microenvironments could unlock new therapeutic strategies

technology for high-throughput screening of pharmacological compound libraries to identify potential therapeutic "Ana Lilia Moreno Salinas (2), Arturo Mancini (1), Raida Jallouli (2), Richard Leduc (2) (1)Domain Therapeutics Laurent Sabbagh on the web Domain Therapeutics Characterizing hADGRE5/CD97 Activation and Signaling: Domain Therapeutics North America Inc., Montreal, Quebec, Canada 3.

The explosion of biomedical data such as in genomics, structural biology, and pharmacology can provide How can we best leverage these exciting new techniques in areas such as protein structure prediction,

From his early work as a technician at Johns Hopkins Hospital to leading biology at Servo Therapeutics years of drug discovery research in the pharmaceutical industry, where he works mainly on GPCRs as therapeutic He is passionate about mechanistic profiling of therapeutic molecules as well as drug discovery in general

protein-coupled receptors (GPCRs) regulate motivated behavior and how these receptors can be targeted for therapeutic distinct signaling pathways with their physiological effects and may serve as the basis for more selective therapeutics

Terry Hébert is a Professor within the Department of Pharmacology & Therapeutics at McGill University

Saraf " My research focuses on evaluating and targeting serotonin 1A receptors for therapeutic outcomes

of GPCRs in disease states to help test the feasibility of using protein-targeted degradation as a therapeutic

This is the kind of advance that matters for anyone building tools, assays, or therapeutics around receptor

biosensors, cryo-EM, photoswitchable ligands, and nanobodies as pharmacological tools and potential therapeutic

Terry Kenakin’s unique course, Development of GPCR Ligands as Therapeutic Drugs , and gain essential signaling and drug discovery Symposium & Workshop - Brazil NEW April 1 - 3, 2025 | 2nd Peptide-Based Therapeutics Summit - USA April 2 - 3, 2025 | New therapeutic modalities: Transforming receptor pharmacology - UK Biologist - Confo Therapeutics Associate Director/Director, Platform & Hit-ID Chemistry Lead - Septerna Pharmacologist - Schrödinger Scientist - Biology - Superluminal Medicines Scientist I Cell Biology - Tectonic Therapeutic

guides program momentum Focus resources where they’ll change outcomes No More Strategy Swirl I build structure up clear deliverables across internal and CRO teams Keep cross-functional teams moving with shared structure

Eric Trinquet —how structured play turns into assays and why serendipity belongs in your build process

.” — Michelle Halls This structure: Multiplied research capacity Attracted talent and funding Created

This could accelerate discovery of therapeutic targets by combining multiplex data with focused downstream As the field advances, the computational layer — including AlphaFold and structural prediction tools

Clear Platform Assessment: Gain rapid, independent insight into GPCR platform risks and true therapeutic Operational Discipline I instill structure and consistency across every phase of your discovery process

Membrane Proteins and Receptors (COMPARE), University of Nottingham, where he provides leadership in structural group leader at the Paul Scherrer Institute and ETH Zürich in Switzerland, changing his attention to structural

. 🧭 Full-Length Course Structure: 4 × 1-hour sessions Purpose: Deep, multi-session learning experience Best for: Comprehensive topics that require exploration and discussion ⚡ Short Course Structure: 1 session coverage of key concepts Best for: Core methods, applied principles, or emerging topics 🔍 Mini Course Structure instructor agreement (you’ll receive the full version right after submission). 🧱 Step 2: Plan Your Course Structure

pipeline ♦️ Celtarys’ validated TR-FRET assay for CB1/CB2 ♦️ Chemokine-GPCR selectivity decoded ♦️ PTH1R structures

It’s structured, organized, and spatially constrained.

Jens Carlsson on predictive modeling—where structure-based design and MD guide experiments (and where

Qing is a structural biologist interested in the molecular mechanisms controlling how class C GPCRs transmit

He is also an Associate Leader of the Experimental Therapeutics and Metabolism Program and the Director

She has advanced the use of computational methods to meet the challenges of designing therapeutics with

Andrew Charles that who specialized in animal models of migraine and delta-opioid receptors as a therapeutic

objectives ✅ Build internal systems and workflows that support scale ✅ Create investor-ready operating structures It is structural. When complexity grows faster than strategy, biotech companies drift.